Checkpoint Therapeutics Inc. (NASDAQ: CKPT)
$2.67
+0.1550 ( +6.17% ) 625.9K
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in theĀ USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Market Data
Open
$2.67
Previous close
$2.51
Volume
625.9K
Market cap
$102.06M
Day range
$2.46 - $2.71
52 week range
$1.30 - $3.62
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 12 | Jan 05, 2024 |
4 | Insider transactions | 1 | Jan 03, 2024 |
8-k | 8K-related | 14 | Dec 18, 2023 |
10-q | Quarterly Reports | 55 | Nov 13, 2023 |
8-k | 8K-related | 14 | Nov 13, 2023 |
8-k | 8K-related | 16 | Oct 03, 2023 |
4 | Insider transactions | 1 | Sep 26, 2023 |
10-q | Quarterly Reports | 56 | Aug 14, 2023 |
8-k | 8K-related | 14 | Aug 14, 2023 |
8-k | 8K-related | 20 | Jul 31, 2023 |